155 related articles for article (PubMed ID: 35954374)
1. COVID-19 and Adult Acute Leukemia: Our Knowledge in Progress.
Modemann F; Ghandili S; Schmiedel S; Weisel K; Bokemeyer C; Fiedler W
Cancers (Basel); 2022 Jul; 14(15):. PubMed ID: 35954374
[TBL] [Abstract][Full Text] [Related]
2. Characteristics, clinical outcomes, and risk factors of SARS-COV-2 infection in adult acute myeloid leukemia patients: experience of the PETHEMA group.
Palanques-Pastor T; Megías-Vericat JE; Martínez P; López Lorenzo JL; Cornago Navascués J; Rodriguez Macias G; Cano I; Arnan Sangerman M; Vidriales Vicente MB; Algarra Algarra JL; Foncillas MÁ; Herrera P; Botella Prieto C; Vives S; Figuera Álvarez Á; Cuevas Palomares L; Sobas M; Contento Gonzalo A; Cuello García R; Amutio Diez ME; De Miguel Llorente D; Navas Elorza B; Bergua Burgues JM; Bernal Del Castillo T; Mateos Rodríguez MC; de Cabo López E; Franco Villegas AC; García Boyero R; Escolano Escobar C; Seri Merino C; Cervero C; Roldán Pérez A; Hermosín Ramos L; Cervera Calvo M; Olave MT; Villafuerte Gutiérrez P; de Laiglesiai A; Serrano J; Najera Irazu MJ; Piñana JL; Sanz MÁ; Martínez-López J; Montesinos P
Leuk Lymphoma; 2021 Dec; 62(12):2928-2938. PubMed ID: 34292118
[TBL] [Abstract][Full Text] [Related]
3. A Case Series of SARS-CoV-2 Omicron Variant in Patients With Acute Leukemia.
Ali EA; Alamin MA; Abu-Tineh M; Ahmed K; Alshurafa A; Rozi W; Yassin MA
Cureus; 2022 May; 14(5):e25196. PubMed ID: 35747002
[TBL] [Abstract][Full Text] [Related]
4. Chronic Lymphocytic Leukemia in the SARS-CoV-2 Pandemic.
Arellano-Llamas AA; Vela-Ojeda J; Hernandez-Caballero A
Curr Oncol Rep; 2022 Feb; 24(2):209-213. PubMed ID: 35061199
[TBL] [Abstract][Full Text] [Related]
5. SARS-CoV-2 Omicron Variant in Patients With Chronic Myeloid Leukemia: A Retrospective Study.
Ali EA; Khamees I; Abu-Tineh M; Qasim H; Alshurafa A; Ahmed K; Malkawi L; Yassin MA
Cureus; 2022 Apr; 14(4):e23863. PubMed ID: 35411288
[TBL] [Abstract][Full Text] [Related]
6. Comprehensive characterization of the antibody responses to SARS-CoV-2 Spike protein finds additional vaccine-induced epitopes beyond those for mild infection.
Garrett ME; Galloway JG; Wolf C; Logue JK; Franko N; Chu HY; Matsen FA; Overbaugh JM
Elife; 2022 Jan; 11():. PubMed ID: 35072628
[TBL] [Abstract][Full Text] [Related]
7. Epidemiological characteristics of 17 imported patients infected with SARS-CoV-2 Omicron variant.
Liu X; Chen M; Zhou Z; Chen D; Mo J; Liu J
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2022 Mar; 47(3):344-351. PubMed ID: 35545327
[TBL] [Abstract][Full Text] [Related]
8. Generation of neutralizing antibodies against Omicron, Gamma and Delta SARS-CoV-2 variants following CoronaVac vaccination.
Silva ARD; Villas-Boas LS; Tozetto-Mendoza TR; Honorato L; Paula A; Witkin SS; Mendes-Correa MC
Rev Inst Med Trop Sao Paulo; 2022; 64():e19. PubMed ID: 35239863
[TBL] [Abstract][Full Text] [Related]
9. The serological prevalence of SARS-CoV-2 infection in patients with chronic myeloid leukemia is similar to that in the general population.
Bonifacio M; Tiribelli M; Miggiano MC; Abruzzese E; Binotto G; Scaffidi L; Cordioli M; Damiani D; Di Bona E; Trawinska MM; Tanasi I; Dubbini MV; Velotta V; Ceccarelli G; Pierdomenico E; Lo Schirico M; Semenzato G; Ruggeri M; Fanin R; Tacconelli E; Pizzolo G; Krampera M
Cancer Med; 2021 Sep; 10(18):6310-6316. PubMed ID: 34464516
[TBL] [Abstract][Full Text] [Related]
10. Clinical Characteristics and Outcomes Among Adults Hospitalized with Laboratory-Confirmed SARS-CoV-2 Infection During Periods of B.1.617.2 (Delta) and B.1.1.529 (Omicron) Variant Predominance - One Hospital, California, July 15-September 23, 2021, and December 21, 2021-January 27, 2022.
Modes ME; Directo MP; Melgar M; Johnson LR; Yang H; Chaudhary P; Bartolini S; Kho N; Noble PW; Isonaka S; Chen P
MMWR Morb Mortal Wkly Rep; 2022 Feb; 71(6):217-223. PubMed ID: 35143466
[TBL] [Abstract][Full Text] [Related]
11. Successful Anti-SARS-CoV-2 Spike Protein Antibody Response to Vaccination in
Jalil M; Rowane M; Rajan J; Hostoffer R
Allergy Rhinol (Providence); 2021; 12():21526567211056239. PubMed ID: 34868726
[TBL] [Abstract][Full Text] [Related]
12. Cross-reactive immunity against the SARS-CoV-2 Omicron variant is low in pediatric patients with prior COVID-19 or MIS-C.
Tang J; Novak T; Hecker J; Grubbs G; Zahra FT; Bellusci L; Pourhashemi S; Chou J; Moffitt K; Halasa NB; Schwartz SP; Walker TC; Tarquinio KM; Zinter MS; Staat MA; Gertz SJ; Cvijanovich NZ; Schuster JE; Loftis LL; Coates BM; Mack EH; Irby K; Fitzgerald JC; Rowan CM; Kong M; Flori HR; Maddux AB; Shein SL; Crandall H; Hume JR; Hobbs CV; Tremoulet AH; Shimizu C; Burns JC; Chen SR; Moon HK; Lange C; Randolph AG; Khurana S
Nat Commun; 2022 May; 13(1):2979. PubMed ID: 35624101
[TBL] [Abstract][Full Text] [Related]
13. Vaccination for SARS-CoV-2 in Hematological Patients.
Riccardi N; Falcone M; Yahav D
Acta Haematol; 2022; 145(3):257-266. PubMed ID: 35220303
[TBL] [Abstract][Full Text] [Related]
14. The British variant of the new coronavirus-19 (Sars-Cov-2) should not create a vaccine problem.
Conti P; Caraffa A; Gallenga CE; Kritas SK; Frydas I; Younes A; Di Emidio P; Tetè G; Pregliasco F; Ronconi G
J Biol Regul Homeost Agents; 2021; 35(1):1-4. PubMed ID: 33377359
[TBL] [Abstract][Full Text] [Related]
15. Nasal delivery of broadly neutralizing antibodies protects mice from lethal challenge with SARS-CoV-2 delta and omicron variants.
Lu J; Yin Q; Pei R; Zhang Q; Qu Y; Pan Y; Sun L; Gao D; Liang C; Yang J; Wu W; Li J; Cui Z; Wang Z; Li X; Li D; Wang S; Duan K; Guan W; Liang M; Yang X
Virol Sin; 2022 Apr; 37(2):238-247. PubMed ID: 35527227
[TBL] [Abstract][Full Text] [Related]
16. Humoral immunity against SARS-CoV-2 variants including omicron in solid organ transplant recipients after three doses of a COVID-19 mRNA vaccine.
Saharia KK; Husson JS; Niederhaus SV; Iraguha T; Avila SV; Yoo YJ; Hardy NM; Fan X; Omili D; Crane A; Carrier A; Xie WY; Vander Mause E; Hankey K; Bauman S; Lesho P; Mannuel HD; Ahuja A; Mathew M; Avruch J; Baddley J; Goloubeva O; Shetty K; Dahiya S; Rapoport AP; Luetkens T; Atanackovic D
Clin Transl Immunology; 2022; 11(5):e1391. PubMed ID: 35505864
[TBL] [Abstract][Full Text] [Related]
17. Anti-SARS-CoV2 antibody-mediated cytokine release syndrome in a patient with acute promyelocytic leukemia.
Hegazy AN; Krönke J; Angermair S; Schwartz S; Weidinger C; Keller U; Treskatsch S; Siegmund B; Schneider T
BMC Infect Dis; 2022 Jun; 22(1):537. PubMed ID: 35692034
[TBL] [Abstract][Full Text] [Related]
18. Safety of systemic anti-cancer treatment in oncology patients with non-severe COVID-19: a cohort study.
van Marcke C; Honoré N; van der Elst A; Beyaert S; Derouane F; Dumont C; Aboubakar Nana F; Baurain JF; Borbath I; Collard P; Cornélis F; De Cuyper A; Duhoux FP; Filleul B; Galot R; Gizzi M; Mazzeo F; Pieters T; Seront E; Sinapi I; Van den Eynde M; Whenham N; Yombi JC; Scohy A; van Maanen A; Machiels JP
BMC Cancer; 2021 May; 21(1):578. PubMed ID: 34016086
[TBL] [Abstract][Full Text] [Related]
19. Comprehensive Treatment of Hematological Patients with SARS-CoV-2 Infection Including Anti-SARS-CoV-2 Monoclonal Antibodies: A Single-Center Experience Case Series.
Boeckel GR; Hölscher SD; Bürger C; Jacob T; Krekeler C; Shumilov E; Reicherts C; Bleckmann A; Lenz G; Vollenberg R; Tepasse PR
Curr Oncol; 2022 Mar; 29(4):2312-2325. PubMed ID: 35448162
[TBL] [Abstract][Full Text] [Related]
20. Minimal Crossover between Mutations Associated with Omicron Variant of SARS-CoV-2 and CD8
Redd AD; Nardin A; Kared H; Bloch EM; Abel B; Pekosz A; Laeyendecker O; Fehlings M; Quinn TC; Tobian AAR
mBio; 2022 Apr; 13(2):e0361721. PubMed ID: 35229637
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
